Lance Eboni I, Casella James F, Everett Allen D, Barron-Casella Emily
Department of Neurology, Kennedy Krieger Institute, Baltimore, MD, USA; Department of Neurology, the Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Pediatrics, Division of Hematology, the Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Proteomics Clin Appl. 2014 Dec;8(11-12):813-27. doi: 10.1002/prca.201400069. Epub 2014 Nov 6.
Biomarker analysis and proteomic discovery in pediatric sickle cell disease has the potential to lead to important discoveries and improve care. The aim of this review article is to describe proteomic and biomarker articles involving neurological and developmental complications in this population. A systematic review was conducted to identify relevant research publications. Articles were selected for children under the age of 21 years with the most common subtypes of sickle cell disease. Included articles focused on growth factors (platelet-derived growth factor), intra and extracellular brain proteins (glial fibrillary acidic protein, brain-derived neurotrophic factor), and inflammatory and coagulation markers (interleukin-1β, l-selectin, thrombospondin-1, erythrocyte, and platelet-derived microparticles). Positive findings include increases in plasma brain-derived neurotrophic factor and platelet-derived growth factor with elevated transcranial Dopplers velocities, increases in platelet-derived growth factor isoform AA with overt stroke, and increases in glial fibrillary acidic protein with acute brain injury. These promising potential neuro-biomarkers provide insight into pathophysiologic processes and clinical events, but their clinical utility is yet to be established. Additional proteomics research is needed, including broad-based proteomic discovery of plasma constituents and blood cell proteins, as well as urine and cerebrospinal fluid components, before, during and after neurological and developmental complications.
儿童镰状细胞病的生物标志物分析和蛋白质组学发现有可能带来重要发现并改善治疗。这篇综述文章的目的是描述涉及该人群神经和发育并发症的蛋白质组学和生物标志物文章。进行了一项系统综述以确定相关研究出版物。选择了患有最常见镰状细胞病亚型的21岁以下儿童的文章。纳入的文章聚焦于生长因子（血小板衍生生长因子）、脑内和细胞外蛋白质（胶质纤维酸性蛋白、脑源性神经营养因子）以及炎症和凝血标志物（白细胞介素-1β、L-选择素、血小板反应蛋白-1、红细胞和血小板衍生微粒）。阳性发现包括血浆脑源性神经营养因子和血小板衍生生长因子随经颅多普勒速度升高而增加、血小板衍生生长因子同工型AA在明显中风时增加、胶质纤维酸性蛋白在急性脑损伤时增加。这些有前景的潜在神经生物标志物为病理生理过程和临床事件提供了见解，但它们的临床实用性尚未确立。在神经和发育并发症之前、期间和之后，还需要进行更多的蛋白质组学研究，包括对血浆成分、血细胞蛋白质以及尿液和脑脊液成分进行广泛的蛋白质组学发现。
